cartitude-1 final results: pfs of cilta-cel in patients with heavily pre-treated r/r myeloma
Published 10 months ago • 125 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
2:25
cartitude-1 final results: cilta-cel in heavily pretreated patients with r/r myeloma
-
1:25
cartitude-1: outcomes of patients with triple-class exposed multiple myeloma treated with cilta-cel
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
![[tctap 2022] coronary taped case session 4: cto](https://i.ytimg.com/vi/p_1J7RsAJCg/mqdefault.jpg)
1:00:13
[tctap 2022] coronary taped case session 4: cto
-
9:25
mgus diagnosis: a step-by-step approach
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
4:53
cartitude-1: latest data & crs in myeloma treated with cilta-cel
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma
-
1:30
cartitude-1: promising initial results of cilta-cel for myeloma
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
1:07
updated results from cartitude-1
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
2:21
cilta-cel versus soc in functionally high-risk myeloma with one prior therapy